secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001178913-23-001809
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab Q1 net loss $8.8M; cash $32.8M; CM-101 Phase 2 NASH trial meets safety endpoint
--------------------------------------------------------------------------------

- Net loss of $8.8M ($0.04 per share) vs $5.1M in Q1 2022; R&D expenses rose to $6.9M from $2.7M.
- Cash, equivalents and short-term deposits $32.8M at March 31, 2023, down from $39.9M at Dec 31, 2022; runway extended through H1 2024.
- CM-101 Phase 2 NASH liver fibrosis trial met primary safety endpoint; showed positive activity on fibrotic and inflammatory biomarkers.
- FDA cleared IND for CM-101 Phase 2 systemic sclerosis trial; initial U.S. sites expected to open mid-2023.
- Phase 2 PSC trial advancing with higher dose cohort; top-line data from double-blind portion expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/0001178913-23-001809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/zk2329704.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-001809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer